[Corrections] Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4

Di |2024-06-15T00:30:01+02:00Giugno 15th, 2024|Categorie: Coronavirus Lancet|

Dattwyler RJ, Arnaboldi PM. Vaccination hesistancy in Lyme borreliosis. Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4—In this Comment, the declaration of interests has been updated. This correction has b...

[Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Di |2024-06-14T00:30:06+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previo...

[Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Di |2024-06-14T00:30:02+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for ...

[Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis

Di |2024-06-14T00:30:01+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

Yearly, about 410 000 patients worldwide develop rifampicin-resistant tuberculosis, resistant to the most powerful first-line tuberculosis drug. In 2012, treatment for rifampicin-resistant tuberculosis constituted mainly regimens of 18 months or longer...

[Correspondence] Survival analysis of patients with cholera admitted to treatment centres in Lusaka, Zambia

Di |2024-06-13T00:30:01+02:00Giugno 13th, 2024|Categorie: Coronavirus Lancet|

Cholera remains a global threat to health security, particularly in sub-Saharan Africa where outbreaks have become frequent, with increased magnitude and fatalities.1,2 While the world is preparing for the next pandemic, we explored clinical outcomes a...

[Correspondence] Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions

Di |2024-06-04T00:30:01+02:00Giugno 4th, 2024|Categorie: Coronavirus Lancet|

We have an ethical imperative to learn from recent influenza H1N1 and COVID-19 pandemics to better prepare for the next one. WHO has highlighted the need for surveillance frameworks that can be implemented across states.1 For any future epidemic or pan...

[Articles] Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies

Di |2024-06-01T00:30:01+02:00Giugno 1st, 2024|Categorie: Coronavirus Lancet|

VLA15 was safe, well tolerated, and elicited robust antibody responses to all six OspA serotypes. These findings support further clinical development of VLA15 using the 180 μg dose and 0-2-6-month schedule, which was associated with the greatest immune...

Torna in cima